None listed
Conditions
Brief summary
Following curative liver resection for HCC, 50%-90% of postoperative death is due to recurrent disease. Any neoadjuvant or adjuvant therapy which decreases or delays the onset of recurrence, improves the results of liver resection. However, there is still no effective neoadjuvant therapy or adjuvant therapy for HCC. We conducted a randomized controlled trial to evaluate the effect of preoperative TACE on survival after resection of HCC.
Interventions
For preoperative TACE group, a vascular catheter for TACE was inserted through the femoral artery using the Seldinger technique, and hepatic angiography was performed. The catheter’s tip was inserted selectively into the left and right hepatic artery, or the tumor-feeding artery when technically possible. An emulsion of 5-Fluorouracil (5-FU) (1 gm), mitomycin C (MMC) (20 mg), cisplatin (5 mg) and lipiodol 10-30 ml (1 to 2 ml/cm diameter of the tumor) was injected. Preoperative TACE was begun wit
For preoperative TACE group, a vascular catheter for TACE was inserted through the femoral artery using the Seldinger technique, and hepatic angiography was performed. The catheter’s tip was inserted selectively into the left and right hepatic artery, or the tumor-feeding artery when technically possible. An emulsion of 5-Fluorouracil (5-FU) (1 gm), mitomycin C (MMC) (20 mg), cisplatin (5 mg) and lipiodol 10-30 ml (1 to 2 ml/cm diameter of the tumor) was injected. Preoperative TACE was begun within 10 days after randomization. TACE was repeated up to 3 times at an interval of 4 to 9 weeks. Partial hepatectomy was performed within 8 weeks from the last session of TACE.
Sponsors
Eastern Hepatobiliary Surgery Hospital
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Preoperative diagnosis of HCC > or =5 cm in diameter suitable for partial hepatectomy
Exclusion criteria
Received other treatment before; history or presence of other malignancies; inadequate liver function
Outcome results
None listed